TARA Launches Cardiotype.Fo, Best-In-Class Assay for Assessment of Cardiac Contractility

September 27, 2018 | News

TARA Launches Cardiotype.Fo, Best-In-Class Assay for Assessment of Cardiac Contractility

New York, (Newswire.com) - TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac contractility. Contractility of heart muscle tissue is a critically important measure of cardiac function and is used routinely to evaluate the safety of biopharmaceutical drug candidates and the efficacy of  therapies under development for the treatment of cardiomyopathy and heart failure.

TARA Biosystems offers bioanalytical testing services on its proprietary cardiac tissue engineering platform known as Biowire™ II. The Biowire™ II platform promotes the maturation of induced pluripotent stem cell (iPSC) derived cardiomyocytes into engineered cardiac tissues that mimic structural, functional, and genetic characteristics of mature human cardiac tissue.  These physiologically-relevant in vitro tissue models enable early cardiac risk assessment of drug discovery candidates and accelerate discovery efforts for novel heart medicines via disease modeling and phenotypic screening capabilities.

Leveraging TARA’s Biowire™ II platform, Cardiotype.Fo is the only in vitro assay on the market that is capable of directly measuring contractile force, rate of contraction and rate of relaxation of engineered human cardiac tissues.  The launch of Cardiotype.Fo follows from successful evaluations of the assay with more than a dozen biopharmaceutical partners to-date.

Biowire™ II was recently recognized by Frost & Sullivan’s 2018 Technology Innovation Award as the leading Heart-On-A-Chip solution in North America.  Frost & Sullivan’s Technology Innovation Award recognizes groundbreaking products with innovative features and functionality that are gaining rapid acceptance in the market.

The TARA team will be showcasing Cardiotype.Fo at Booth #212 at the upcoming 2018 Safety Pharmacology Society (SPS) Annual Meeting in Washington, DC (September 30, 2018 to October 3, 2018).  Please stop by our booth to learn more about Cardiotype.Fo or contact us in advance to schedule a private meeting with our team (BD@tarabiosystems.com).

 

About TARA Biosystems

TARA Biosystems, Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and risk assessment. TARA Biosystems offers a high fidelity solution that is based on human iPSC derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The TARA platform allows pharma to access human cardiac information on therapeutics candidates earlier in the drug development cycle.  For more information, please visit: www.tarabiosystems.com.

 

Press Contacts:

Donna See

TARA Biosystems, Inc.

917-512-3037

donna@tarabiosystems.com

Contact

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.

TARA
430 East 29th Street
Suite #1015
New York, NY 10016
USA
info@tarabiosystems.com